Skip to main
NVAX
NVAX logo

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 40%
Buy 0%
Hold 0%
Sell 40%
Strong Sell 20%

Bulls say

Novavax Inc is developing a traditional antigen-based vaccine platform, which may be more favorably perceived in the current regulatory climate compared to mRNA-based alternatives. The company has demonstrated strong clinical results in its malaria and influenza vaccine programs, highlighting the versatility of its platform beyond its initial COVID-19 vaccine. Additionally, there are several potential upsides to revenue forecasts, including strategic partnerships, earlier-than-expected product approvals, and increased pricing or adoption rates for its marketed vaccines.

Bears say

Novavax Inc. is expected to experience a decline in total revenues in the short term due to significant payouts related to the Sanofi deal, raising concerns about immediate financial stability. The company's strategy to cut costs includes a reduction in research and development and selling, general, and administrative expenses from $1.2 billion in 2023 to $250 million by 2027, indicating potential challenges in maintaining operational effectiveness. This combination of reduced revenues and aggressive cost-cutting measures may adversely affect the company's ability to achieve sustainable growth and profitability in the near future.

Novavax (NVAX) has been analyzed by 5 analysts, with a consensus rating of Hold. 40% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 40% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 5 analysts, Novavax (NVAX) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.